Streetbeat News

Price Targets

WFC

Raymond James analyst David Long has maintained a Strong Buy rating on Wells Fargo (NYSE:WFC) and raised the price target from $48 to $51.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 11:16 am

LFMD

HC Wainwright & Co. analyst Yi Chen has initiated coverage on LifeMD (NASDAQ:LFMD) with a Buy rating and a price target of $9.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 11:15 am

AGEN

HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating on Agenus (NASDAQ:AGEN) and maintained an $8 price target.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 10:13 am

RWLK

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on ReWalk Robotics (NASDAQ:RWLK) and maintained a $3 price target.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 10:13 am

ETON

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Eton Pharmaceuticals (NASDAQ:ETON) but lowers the price target from $10 to $9.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 10:11 am

ENSC

HC Wainwright & Co. analyst Raghuram Selvaraju has initiated coverage on Ensysce Biosciences (NASDAQ:ENSC) with a Buy rating and a price target of $9.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 10:10 am

BTAI

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on BioXcel Therapeutics but lowers the price target from $66 to $60.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 10:09 am

BLCO

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Bausch & Lomb (NYSE:BLCO) and maintained a price target of $22.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 10:08 am

MITK

HC Wainwright & Co. analyst Scott Buck has reiterated a 'Buy' rating on Mitek Systems (NASDAQ:MITK) and maintained a $19 price target.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 10:04 am

FEMY

Chardan Capital analyst Keay Nakae has reiterated a 'Buy' rating on Femasys (NASDAQ:FEMY) and maintained a price target of $10.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 10:03 am